A detailed history of King Luther Capital Management Corp transactions in Amgen Inc stock. As of the latest transaction made, King Luther Capital Management Corp holds 517,967 shares of AMGN stock, worth $137 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares
517,967
Previous 511,380 1.29%
Holding current value
$137 Million
Previous $160 Million 4.45%
% of portfolio
0.73%
Previous 0.73%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$309.38 - $337.38 $2.04 Million - $2.22 Million
6,587 Added 1.29%
517,967 $167 Million
Q2 2024

Aug 12, 2024

SELL
$262.75 - $319.31 $141,622 - $172,108
-539 Reduced 0.11%
511,380 $160 Million
Q1 2024

May 13, 2024

SELL
$268.87 - $324.56 $3.7 Million - $4.46 Million
-13,750 Reduced 2.62%
511,919 $146 Million
Q4 2023

Feb 09, 2024

BUY
$255.7 - $288.46 $630,556 - $711,342
2,466 Added 0.47%
525,669 $151 Million
Q3 2023

Nov 13, 2023

BUY
$218.65 - $271.46 $125,067 - $155,275
572 Added 0.11%
523,203 $141 Million
Q2 2023

Aug 10, 2023

SELL
$214.27 - $253.37 $3.21 Million - $3.8 Million
-14,990 Reduced 2.79%
522,631 $116 Million
Q1 2023

May 11, 2023

SELL
$225.79 - $275.2 $492,222 - $599,936
-2,180 Reduced 0.4%
537,621 $130 Million
Q4 2022

Feb 13, 2023

SELL
$229.03 - $291.01 $401,489 - $510,140
-1,753 Reduced 0.32%
539,801 $142 Million
Q3 2022

Nov 10, 2022

SELL
$224.46 - $253.15 $933,080 - $1.05 Million
-4,157 Reduced 0.76%
541,554 $122 Million
Q2 2022

Aug 11, 2022

SELL
$230.71 - $256.74 $530,171 - $589,988
-2,298 Reduced 0.42%
545,711 $133 Million
Q1 2022

May 11, 2022

SELL
$219.27 - $242.57 $119,282 - $131,958
-544 Reduced 0.1%
548,009 $133 Million
Q4 2021

Feb 14, 2022

SELL
$198.88 - $227.6 $910,472 - $1.04 Million
-4,578 Reduced 0.83%
548,553 $123 Million
Q3 2021

Nov 10, 2021

SELL
$212.27 - $248.7 $3.84 Million - $4.49 Million
-18,068 Reduced 3.16%
553,131 $118 Million
Q2 2021

Aug 13, 2021

SELL
$233.58 - $259.14 $2.57 Million - $2.86 Million
-11,022 Reduced 1.89%
571,199 $139 Million
Q1 2021

May 12, 2021

SELL
$221.91 - $258.6 $1.5 Million - $1.75 Million
-6,755 Reduced 1.15%
582,221 $145 Million
Q4 2020

Feb 10, 2021

SELL
$216.38 - $257.67 $2.24 Million - $2.67 Million
-10,352 Reduced 1.73%
588,976 $135 Million
Q3 2020

Nov 12, 2020

SELL
$234.65 - $260.95 $769,652 - $855,916
-3,280 Reduced 0.54%
599,328 $152 Million
Q2 2020

Aug 12, 2020

BUY
$197.81 - $242.74 $234,404 - $287,646
1,185 Added 0.2%
602,608 $142 Million
Q1 2020

May 13, 2020

SELL
$182.24 - $241.7 $2.03 Million - $2.69 Million
-11,128 Reduced 1.82%
601,423 $122 Million
Q4 2019

Feb 12, 2020

SELL
$189.21 - $243.2 $333,388 - $428,518
-1,762 Reduced 0.29%
612,551 $148 Million
Q3 2019

Nov 12, 2019

SELL
$174.11 - $208.62 $2.26 Million - $2.71 Million
-12,999 Reduced 2.07%
614,313 $119 Million
Q2 2019

Aug 12, 2019

SELL
$166.7 - $195.41 $662,299 - $776,363
-3,973 Reduced 0.63%
627,312 $116 Million
Q1 2019

May 10, 2019

BUY
$180.87 - $203.88 $2.35 Million - $2.65 Million
13,017 Added 2.11%
631,285 $120 Million
Q4 2018

Feb 12, 2019

BUY
$178.4 - $208.25 $1.96 Million - $2.29 Million
10,976 Added 1.81%
618,268 $120 Million
Q3 2018

Nov 13, 2018

SELL
$185.29 - $208.89 $248,288 - $279,912
-1,340 Reduced 0.22%
607,292 $126 Million
Q2 2018

Aug 13, 2018

SELL
$166.05 - $186.51 $833,903 - $936,653
-5,022 Reduced 0.82%
608,632 $112 Million
Q1 2018

May 08, 2018

BUY
$169.43 - $198.0 $2.07 Million - $2.41 Million
12,195 Added 2.03%
613,654 $105 Million
Q4 2017

Feb 12, 2018

BUY
$168.79 - $188.59 $3,375 - $3,771
20 Added 0.0%
601,459 $105 Million
Q3 2017

Nov 13, 2017

BUY
$167.29 - $191.0 $101 Million - $115 Million
601,439
601,439 $112 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track King Luther Capital Management Corp Portfolio

Follow King Luther Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of King Luther Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on King Luther Capital Management Corp with notifications on news.